|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:1997
gptkb:2006
gptkb:FDA
|
|
gptkbp:associated_with
|
gptkb:granulomatosis_with_polyangiitis
gptkb:microscopic_polyangiitis
gptkb:Oncology
gptkb:multiple_sclerosis
B-cell malignancies
B-cell autoimmune disorders
|
|
gptkbp:available_on
|
gptkb:biotechnology
generic version
|
|
gptkbp:bioavailability
|
gptkb:Rituximab_biosimilars
|
|
gptkbp:brand
|
gptkb:Rituxan
|
|
gptkbp:can_be_combined_with
|
gptkb:methotrexate
|
|
gptkbp:chemical_formula
|
C6420 H9920 N1710 O1980 S44
C6428 H9924 N1716 O1984 S46
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
oncology
hematology
rheumatology
|
|
gptkbp:contraindication
|
active infections
severe allergic reactions
history of severe allergic reactions
severe immunosuppression
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:discovered_by
|
1990s
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:duration
|
varies
|
|
gptkbp:financial_stability
|
24 months
|
|
gptkbp:first_introduced
|
gptkb:1997
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rituximab
|
|
gptkbp:indication
|
gptkb:granulomatosis_with_polyangiitis
gptkb:microscopic_polyangiitis
autoimmune diseases
|
|
gptkbp:influenced_by
|
monoclonal antibody technology
|
|
gptkbp:influences
|
inflammatory response
immune system
autoimmune response
|
|
gptkbp:interacts_with
|
live vaccines
other biologics
immunosuppressive drugs
|
|
gptkbp:invention
|
gptkb:2016
|
|
gptkbp:is_monitored_by
|
infusion reactions
blood cell counts
blood counts
infection signs
|
|
gptkbp:is_used_for
|
gptkb:Oncology
gptkb:Non-Hodgkin_lymphoma
gptkb:non-Hodgkin_lymphoma
gptkb:Chronic_lymphocytic_leukemia
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
multiple countries
|
|
gptkbp:mechanism_of_action
|
depletes B cells
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:produced_by
|
gptkb:Genentech
Chinese hamster ovary cells
|
|
gptkbp:research
|
gptkb:disease
gptkb:chronic_fatigue_syndrome
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:Sjogren's_syndrome
gptkb:myasthenia_gravis
gptkb:Canis_lupus
gptkb:systemic_sclerosis
gptkb:multiple_sclerosis
gptkb:Open_VMS
gptkb:dermatomyositis
gptkb:sarcoidosis
clinical trials
fibromyalgia
psoriasis
anemia of chronic disease
combination therapies
biomarker studies
other autoimmune diseases
transplantation
thrombotic thrombocytopenic purpura
long-term effects studies
pharmacokinetics studies
chronic urticaria
hemophagocytic lymphohistiocytosis
chronic pain syndromes
idiopathic thrombocytopenic purpura
adult-onset Still's disease
pediatric autoimmune diseases
relapsing polychondritis
|
|
gptkbp:research_focus
|
cancer immunotherapy
autoimmune disease treatment
B-cell depletion therapy
|
|
gptkbp:route_of_administration
|
IV
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
gptkb:progressive_multifocal_leukoencephalopathy
fatigue
headache
nausea
fever
neurological symptoms
cardiovascular events
skin reactions
infections
increased risk of infections
hypotension
infusion reactions
hypersensitivity reactions
gastrointestinal symptoms
pulmonary toxicity
tumor lysis syndrome
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:suitable_for
|
pregnant women
breastfeeding women
|
|
gptkbp:targets
|
CD20 protein
|
|
gptkbp:trade
|
gptkb:Rituxan
|
|
gptkbp:used_for
|
gptkb:rheumatoid_arthritis
treatment of rheumatoid arthritis
treatment of chronic lymphocytic leukemia
treatment of non-Hodgkin lymphoma
|
|
gptkbp:website
|
IV site
|
|
gptkbp:weight
|
143 k Da
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
4
|